Alglucosidase alfa - Sanofi
Alternative Names: Alglucosidase alpha; GZ419829; human acid alpha-glucosidase; Lumizyme; Myozyme; Pompase; recombinant human acid alpha-glucosidase; rhGAALatest Information Update: 05 Nov 2023
At a glance
- Originator Genzyme Corporation
- Developer Sanofi
- Class Alpha-glucosidases; Recombinant proteins
- Mechanism of Action Alpha-glucosidase replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Glycogen storage disease type II
Most Recent Events
- 22 Apr 2017 Long term efficacy pooled data from a phase III and phase IV trial in Glycogen-storage-disease-type-II presented at the 69th Annual Meeting of the American Academy of Neurology (AAN-2017)
- 01 Aug 2014 US FDA approves sBLA for alglucosidase alfa (Lumizyme®) for patients of any age or phenotype with Glycogen storage disease type II in USA
- 02 Sep 2013 Genzyme initiates enrolment in the phase IV PAPAYA trial for Pompe's disease in US, Germany, India, Russia and Ukraine (NCT01410890)